


For Research Use Only. NOT for Use in Diagnostic Procedures.

A Novel Extraction for Synthetic Cannabinoids in Human Whole Blood Using Supported Liquid Extraction Prior to LC-MS/MS Analysis

Author: Rebecca Mastrovito, NMS Labs, 200 Welsh Road, Horsham PA USA.



Rebecca Mastrovito M.S. is currently employed as a Research and Development Associate II at NMS Labs in Horsham, PA, USA. For the past four years, she has been responsible for the development of their novel psychoactive substance portfolio. She has been recently published in a peer-reviewed journal for her work with phosphatidylethanol.

Introduction

Synthetic Cannabinoids are a sub-category of Novel Psychoactive Substances (NPS). Novel psychoactive substances refer to emerging substances that have been structurally modified from existing regulated substances. Synthetic cannabinoids are structurally related to tetrahydrocannabinol (THC), agonists of the CB₁ and CB₂ receptors. Synthetic cannabinoids are sold under a wide range of names such as K₂, Spice, Legal Highs¹. They can be easily found online and in convenience stores as dried plant material or liquids for e-cigarettes. The EMCDDA identified 190 new synthetic cannabinoids that were reported in 2019 as part of the early warning system¹. These compounds have been synthesized specifically to circumvent existing laws regarding drug control and scheduling guidelines. These substances pose a significant public health concern due to their unknown potency and wide array of side effects. According to the EMCDDA, symptoms including agitation, nausea, psychosis, stroke, mass poisoning, and even death².

The development of a novel high-pressure liquid chromatography/triple quad mass spectrometry method allows for the efficient and accurate identification of 12 synthetic cannabinoids in whole blood by LC-MS/MS. Samples are fortified with internal standard, buffered, and extracted using Supported Liquid Extraction (SLE).

Analytes

APP-BINACA, ADB-FUBINACA, 5-Fluoro CUMYL-P7AICA, 4-cyano CUMYL-BINACA, 5-Fluoro-MDMB-PICA, 4-Fluoro-MDMB-BINACA, ADB-CHMINACA, MMB-FUBINACA, 5-Fluoro-ADB/5-Fluoro-AEB, 5-Fluoro-CUMYL-PINACA, MDMB-4en-PINACA, CUMYL-PeGACLONE




Figure 1. Synthetic Cannabinoid Structures.

Sample Preparation Procedure

Format

ISOLUTE® SLE+ 1 mL Supported Liquid Extraction Columns, Part Number 820-0140-CG.

Sample Pre-Treatment

Whole blood samples were fortified and 500 µL of sample, calibrators, and controls were aliquoted into extraction tubes. Each sample was fortified with 25 µL of internal standard and vortexed to mix. Samples were buffered with 500 µL of deionized water and vortexed.

Sample Loading

750 µL of buffered sample was loaded onto the SLE+ column with an appropriate collection tube in place. Positive pressure (2–5 psi) was applied using a Biotage PRESSURE+ 48 Positive Pressure Manifold to initiate flow of sample on the column. The sample was allowed to absorb for 5 minutes.

Analyte Elution

Add 2 mL of ethyl acetate and gravity elute. Using positive pressure, push through any remaining solvent. Repeat, by adding 2 mL ethyl acetate and gravity elute. Using positive pressure, push through any remaining solvent.

Post Extraction

The extracts were evaporated using a Biotage TurboVap® LV utilizing a ramped flow method: 1.5 L/min for 5 min and then 2.5 L/min until dryness. The water bath temperature was set at 30 °C.

Reconstitution

Samples were reconstituted by adding 200 µL of 50:50 (v/v) methanol/deionized water with 1% formic acid.

HPLC Conditions

Instrument

Waters UPLC® Acquity System Xevo TQS (Waters, Milford, MA, USA)

Column

Waters Acquity BEH C18 (100 mm x 2.1mm, 1.7 µm)

Mobile Phase

A: High Purity Deionized Water with 0.1% Formic acid

B: High Purity Methanol and Acetonitrile (80:20)

Flow Rate

0.4 mL/min

Injection Volume

10 µL

Column Temperature

50 °C

Table 1. HPLC Gradient conditions.

Step	Time (min.)	Flow Rate (mL/min.)	%A	%B
1	0	0.4	60	40
2	3	0.4	20	80
3	4	0.4	10	90
4	4.1	0.4	5	95
5	4.5	0.4	5	95

MS Conditions

All experiments were carried out on a UPLC® system (Waters Acquity System, Waters, Manchester, UK) coupled to a tandem-quadrupole mass spectrometer (Xevo TQS, Waters, Milford, MA, USA). MS/MS detection was performed utilizing electrospray ionization (ESI) operating in positive ion mode with multiple reaction monitoring (MRM). The capillary voltage was set to 1.0 kV, the source temperature was 150 °C and the nitrogen desolvation gas was heated to 400 °C with a flow rate of 800L/h.

Table 2. MS conditions and retention times for target analytes.

Analyte	M+1	Collision	RT
APP BINACA	365.3 > 201.2 365.3 > 320.3	24 14	2.47
ADMB FUBINACA	383.1 > 253 383.1 > 109	24 46	2.48
5F CUMYL P7AICA	368.2 > 250 368.2 > 119	14 32	2.65
4 cyano CUMYL BINACA	361.1 > 226.1 361.1 > 243.1	22 10	2.73
5F MDMB PICA	377.2 > 232.1 377.2 > 144.1	16 38	3.00
4F MDMB BINACA	364.3 > 219.2 364.3 > 304.3	24 14	3.05
ADMB CHMINACA	371.1 > 326.1 371.1 > 241.1	16 26	3.12
MMB-FUBINACA	384.3 > 253.2 384.3 > 109.1	22 38	3.13
5F ADB/5F-AEB	378.2 > 145.1 378.2 > 233.2	38 22	3.28
5F CUMYL PINACA	368.1 > 233 368.1 > 213	18 28	3.40
MDMB-4en-PINACA	358.2 > 298.2 358.2 > 171.1	24 16	3.65
CUMYL PeGACLONE	373.2 > 255 373.2 > 119	10 26	3.79

Results/Discussion

Analytical standards from Cayman Chemical (Ann Arbor, Michigan) were prepared in methanol and further diluted to the respective concentrations for calibrators and controls (see Table 3). A bulk serum cut-off calibrator, positive and negative controls were prepared by aliquoting 50 µL of the bulk serum material into 950 µL of whole blood.

Chromatographic separation is achieved over an elution gradient using a C18 column outlined in Table 1. The extracted ion chromatograms (see Figure 2) and the observed retention times for all of the analytes are listed in Table 2. The observed recovery was > 60% for all compounds shown in Figure 3.




Figure 2. Method Chromatogram. (A) ADBM FUBINACA (B) APP BINACA (C) 5-Fluoro CUMYL P7AICA (D) 4-cyano CUMYL BINACA (E) 5-Fluoro MDMB PICA (F) 4-Fluoro MDMB BINACA (G) MMB-FUBINACA (H) 5-Fluoro ADB/5-Fluoro EMB (I) ADBM CHMINACA (J) 5-Fluoro CUMYL PINACA (K) MDMB 4en PINACA (L) CUMYL PeGACLONE.




Figure 3. Recoveries for synthetic cannabinoids in blood at reporting limit using ISOLUTE® SLE+ 1 mL column.

Table 3. Reporting limits for all respective compounds.

Analyte	Reporting Limit (ng/mL)
APP BINACA	0.1
4 cyano CUMYL BINACA	0.1
5F MDMB PICA	0.1
4F MDMB BINACA	0.1
ADMB CHMINACA	0.1
MMB-FUBINACA	0.1
5F CUMYL PINACA	0.1
MDMB-4en-PINACA	0.1
5F ADB/5F-AEB	0.2
5F CUMYL P7AICA	0.5
CUMYL PeGACLONE	0.5
ADMB FUBINACA	1.0




Figure 4. Individual chromatograms at the LOQ.

Conclusion

This ISOLUTE® SLE+ extraction method with analysis by LC-MS/MS extracted the novel synthetic cannabinoids from whole blood with recoveries of greater than 60%.

Ordering Information

Part Number	Description	Quantity
820-0140-CG	ISOLUTE® SLE+ Supported Liquid Extraction Columns 1 mL Sample Volume (Tablets)	30
415000	Biotage TurboVap® LV	1
PPM-48	Biotage® PRESSURE+ 48 Positive Pressure Manifold	1

References

1. EU Drug Markets Report (2019). Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction; http://www.emcdda.europa.eu/system/files/publications/12078/20192630_TD0319332ENN_PDF.pdf. DOI: 10.2810/796253TD (Accessed 2/7/2020)
2. PERSPECTIVES ON DRUGS: Synthetic cannabinoids in Europe (2019). Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction; http://www.emcdda.europa.eu/system/files/publications/2753/POD_Synthetic%20cannabinoids_o.pdf (Accessed 2/7/2020)

EUROPE

Main Office: +46 18 565900
 Toll Free: +800 18 565710
 Fax: +46 18 591922
 Order Tel: +46 18 565710
 Order Fax: +46 18 565705
order@biotage.com
 Support Tel: +46 18 56 59 11
 Support Fax: +46 18 56 57 11
eu-1-pointsupport@biotage.com

NORTH & LATIN AMERICA

Main Office: +1 704 654 4900
 Toll Free: +1 800 446 4752
 Fax: +1 704 654 4917
 Order Tel: +1 704 654 4900
 Order Fax: +1 434 296 8217
ordermailbox@biotage.com
 Support Tel: +1 800 446 4752
 Outside US: +1 704 654 4900
us-1-pointsupport@biotage.com

JAPAN

Tel: +81 3 5627 3123
 Fax: +81 3 5627 3121
jp_order@biotage.com
jp-1-pointsupport@biotage.com

CHINA

Tel: +86 21 68162810
 Fax: +86 21 68162829
cn_order@biotage.com
cn-1-pointsupport@biotage.com

KOREA

Tel: +82 31 706 8500
 Fax: +82 31 706 8510
korea_info@biotage.com
kr-1-pointsupport@biotage.com

INDIA

Tel: +91 22 4005 3712
india@biotage.com

Distributors in other regions
 are listed on www.biotage.com

Literature Number: AN944.V.1

© 2020 Biotage. All rights reserved. No material may be reproduced or published without the written permission of Biotage. Information in this document is subject to change without notice and does not represent any commitment from Biotage. E&OE. A list of all trademarks owned by Biotage AB is available at www.biotage.com/legal. Other product and company names mentioned herein may be trademarks or registered trademarks and/or service marks of their respective owners, and are used only for explanation and to the owners' benefit, without intent to infringe. **FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.**